Lv1
37 积分 2025-03-06 加入
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
6小时前
待确认
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials
6小时前
待确认
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials
6小时前
已完结
THE DOSE-RESPONSE OF INHALED CORTICOSTEROIDS IN COMBINATION ICS/LABA MAINTENANCE THERAPY FOR ASTHMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
2天前
已关闭
THE DOSE-RESPONSE OF INHALED CORTICOSTEROIDS IN COMBINATION ICS/LABA MAINTENANCE THERAPY FOR ASTHMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
4天前
已关闭
Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study
2个月前
已完结
Asthma
5个月前
已完结
Asthma
5个月前
已关闭
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
6个月前
已完结
慢性鼻窦炎诊断和治疗指南（2024）
6个月前
已完结
皖公网安备34019202002308
